Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix

中和 效力 抗体 药效学 药代动力学 体外 单克隆抗体 药理学 中和抗体 病毒学 体内 病毒 安慰剂 医学 不利影响 治疗指标 免疫学 临床试验 生物 单克隆 化学 重组DNA 分子生物学
作者
Francesco Borriello,Gavin C. K. W. Koh,Iñaki F Troconiz,Rounak Nassirpour,Lovely Goyal,Anvar Suyundikov,Akber Safder,Nicholas Robertson,Anna Allen,Andrew W. Robertson,Stephanie Straley,Pam Farmer,Denise Murphy,Eric Carlin,Kimberly P. Schmitt,Amarendra Pegu,Daria J. Hazuda,Alexandra Snyder,Dinesh P. de Alwis
出处
期刊:The Journal of Infectious Diseases [Oxford University Press]
卷期号:234 (5): 747-757
标识
DOI:10.1093/infdis/jiag349
摘要

BACKGROUND: Antibodies against the SARS-CoV-2 spike receptor-binding domain provided effective COVID-19 treatment until resistant variants emerged. GB-0669 is a half-life-extended monoclonal antibody optimized using artificial intelligence. It targets the conserved spike S2 stem helix, a region subject to limited selective pressure from antibody responses induced by natural infection or vaccination. METHODS: Preclinical safety studies were conducted in cynomolgus monkeys. In the first-in-human trial, healthy adults aged 18-55 received single intravenous doses of GB-0669 or placebo in 5 ascending cohorts (100, 300, 600, 1200, and 2400 mg). Participants were monitored for 43 weeks to evaluate safety, pharmacokinetics (PK), and pharmacodynamics (PD; serum live virus neutralization). In vitro studies assessed neutralization of GB-0669 combined with antiviral drugs (remdesivir, nirmatrelvir, and molnupiravir). RESULTS: Preclinical studies revealed no safety concerns. In the clinical trial (n = 51; 36 GB-0669, 15 placebo), GB-0669 was well-tolerated without dose-limiting toxicities; all adverse reactions were mild (Grade 1 or 2). Pharmacokinetics showed dose proportionality up to 2400 mg, with a half-life of 54 days. Dose-dependent increases in serum live virus neutralization occurred at 600 and 1200 mg, with separation from placebo. The estimated neutralizing index that adjusts GB-0669 serum concentrations for its in vitro neutralizing potency supported therapeutic efficacy for 2 weeks post-administration. Finally, in vitro experiments showed improved neutralization profiles of GB-0669 in combination with antivirals. CONCLUSIONS: The data support exploring GB-0669 at 1200 mg in a Phase 2 trial for treating COVID-19 in immunocompromised individuals. The combination of GB-0669 with antiviral drugs may offer additional therapeutic benefits. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov Identifier. NCT07050511.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
weitao0916完成签到,获得积分10
1秒前
冬冬完成签到,获得积分10
2秒前
小蘑菇的应助被杨淼采纳,获得10
2秒前
爱听歌的沛儿完成签到 ,获得积分20
2秒前
2秒前
3秒前
4秒前
李健的小迷弟的应助被晓天采纳,获得10
4秒前
张伟的应助被钱罐罐采纳,获得10
4秒前
Zzha10发布了新的文献求助10
4秒前
4秒前
是我呀吼发布了新的文献求助20
5秒前
Orange的应助被土豪的城采纳,获得30
7秒前
XS_QI发布了新的文献求助10
7秒前
还有早安完成签到,获得积分10
7秒前
安详的夜春完成签到,获得积分10
7秒前
小鱼干完成签到,获得积分10
7秒前
自由的王发布了新的文献求助10
8秒前
开朗紫发布了新的文献求助10
8秒前
叶95完成签到,获得积分10
9秒前
9秒前
10秒前
10秒前
Maestro_S的应助被小鱼干采纳,获得10
11秒前
11秒前
吕锴岐完成签到 ,获得积分10
12秒前
huang完成签到 ,获得积分10
12秒前
12秒前
zjjcug完成签到,获得积分10
12秒前
苦昼短完成签到 ,获得积分10
12秒前
zzl完成签到,获得积分10
12秒前
大个的应助被小青采纳,获得10
13秒前
anqi6688完成签到,获得积分10
13秒前
Zzha10完成签到,获得积分10
13秒前
CarryLJR发布了新的文献求助10
13秒前
充电宝的应助被生而追梦不止采纳,获得10
14秒前
张伟的应助被漫漫采纳,获得10
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568